Thursday, 11 June 2020

Worldwide Urethritis Market Witness A Remarkable Growth Projected By 2023

Urethritis is an inflammation of the urethra, or the tube that carries urine. It shows various symptoms such as pain while urinating and an increased urge to urinate. Additionally, burning sensation while urinating, presence of blood in the semen or urine, frequent urge and discomfort while urinating, abnormal discharge from the vagina or penis, etc. are other common symptoms. Other serious manifestation of urethritis include damage to the reproductive system, pelvic inflammatory disease (PID), which can result in infertility, and others. The primary cause of urethritis is usually infection by bacteria, while viral infection for pre-existing sexually transmitted diseases being the secondary cause. Urethritis is also caused by mechanical or chemical damage to the urethra during treatment or catheterization. Urethritis should not be confused with urinary tract infection (UTI). Urethritis is an inflammation of the urethra, while a UTI is an infection of the urinary tract and both may have similar symptoms, but often require different treatment.
Urethritis Market size is expected to reach USD 18.0 billion by 2023 at a CAGR of ~ 8.0 % during the forecast period 2019-2023.
Females have a greater chance of developing urethritis than males because of the nearness of urethra to the anus, which increases the chance of microbial infection. Also men’s urethras is much longer than women’s. According to the Centers for Disease Control and Prevention (CDC), causative organisms associated with urethritis include Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Human papillomavirus (HPV),  Herpes simplex virus (HSV), and Cytomegalovirus (CMV) and others. According to Antimicrobe, Nongonococcal bacteria caused urethritis in approximately 4 million Americans in 2015 accounting for 80% of the cases. According to Department of Health, U.K., urethritis accounts for 0.005% of hospital consulting with a high 97% of hospital consulting for urethritis requiring hospital admission. Almost 20% of hospital admissions for urethritis requires an emergency.
Rising demand for the treatment due to growing population, increasing screening, rising number of geriatrics, rising safety and success of drug treatment, the extricating nature of the pain, and others are driving the growth of the market. However, complications of treatment such as side effects, emergence of bacterial resistance to antibiotics, cost of urethritis treatment, and others may hamper the urethritis treatment market growth.
Key Players in the Global Urethritis Market
  • Hoffmann-La Roche AG,
  • GlaxoSmithKline,
  • AbbVie,
  • Johnson & Johnson, and Merck & Co.,
  • Eli Lilly and Company,
  • Bristol-Myers Squibb Company,
  • Bayer AG,
  • AstraZeneca plc. and others.
Segments
The global urethritis market has been segmented on the basis of types, diagnosis, drug treatment, and end user.
Based on the types, the market has been segmented as infective urethritis and nonspecific urethritis.
Based on the diagnosis, the market has been segmented as physical examination, microbial culture tests, and others.
Based on the drug treatment, the market has been segmented as pain killers, anti-bacterials, antivirals, and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.
Global Urethritis Market Regional Analysis
The Americas accounts for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of hospitalization procedures due to greater healthcare penetration in the U.S. and Canada drives the urethritis market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates are adding fuel to the market growth. The consolidation of large healthcare players in the U.S. also leads the growth of the market due to increased  buying power of the healthcare players.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future urethritis market in the region.
Europe is the second largest market in the world due to growing healthcare industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to the large pharmaceutical industry.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Posted by at No comments:

Global Diastematomyelia Market Highlights With Leading Players By 2023

Market Scenario
Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.
A number of diagnostic procedures are available in the market for the diagnosis of the diastematomyelia. Increasing healthcare expenditure and rising government support have supported the growth of the market. According to the Boston Children's Hospital, in 2015, 5% of children across the globe were suffering from sustain spinal cord injuries. Furthermore, rapid development in the imaging technology and continuous improvement in the medical services have fuelled the market growth. The cost associated with the surgeries is very high which is not affordable for the people in developing region. Thus, high cost of surgeries, and lack of the precise treatment may restrain the growth of the diastematomyelia market trends.
The Global Diastematomyelia Market is expected to grow at a CAGR of 8.3% during forecast period 2017-2023.
Key players
The major key players in the global diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)
SegmentationThe global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.
On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).
On the basis of host, the market is segmented into children and adults.
On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.
Regional Analysis
Asia Pacific is the fastest growing region in the global diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.
The Americas dominates the global diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.
Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.
Whereas, the Middle East & Africa owns the least share of the global diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market.
Browse more details of Bone Density Test Market @  https://www.marketresearchfuture.com/reports/diastematomyelia-market-4794 
Posted by at No comments:

World Hip Tendinitis Market Estimation Of Top Key Players Shares, Revenue, Analysis And Forecasts Till 2023

Market Scenario:
The rising geriatric population is a major factor expected to drive the expansion of the hip tendinitis market over the next few years. The population of older adults is increasing at a higher rate than any other age group as analyzed by the World Health Organization (WHO). Its statistical observations further suggest that the number of people over 60 years is anticipated to exceed 2 billion mark by the end of 2050. It is projected to act as a growth catalyst for the hip tendinitis market over the next couple of years.
Hip tendonitis is a condition where the tendons present in the hip and pelvis joints that support the bodyweight get damaged. Multiple factors have been recognized that triggers the disease and is likely to affect a larger section of the population in the years to come. Market Research Future (MRFR)’s assessment has asserted that the global hip tendinitis market growth is expected to expand at a CAGR of 4.55% during the forecast period 2017 to 2023. It is also expected to scale a decent valuation by the end of the forecast period.
The concerns raised by the sedentary lifestyle is motivating the masses to shift towards sports and other physical activities for maintaining health and avoiding cardiovascular diseases. However, a drastic increase in injuries during sports has been observed in the recent years. This is one of the major factors responsible for the expansion of the hip tendinitis market currently. It is anticipated to has a similar influence on the growth pattern of the market in the forthcoming years.
Some of the other factors that are likely to boost the growth pace of the hip tendinitis market in the forthcoming future are lack of exercise, research & development, and increasing patient population of rheumatoid arthritis & diabetes. This, is projected to encourage the key players to focus on the development of more effective drugs and diagnosis, thus, augmenting the hip tendinitis market in the foreseeable future.
Key players for global hip tendinitis market
  • Almatica Pharma, Inc
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Merck & Co., Inc
  • Pfizer
  • Abbott
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Geri-Care Pharmaceuticals.
  • Perrigo Company
Segmentation
The global hip tendinitis market is segmented on the basis of types, treatment, and end users.
On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.
On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.
On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others. 
Regional Analysis
The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.
Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.
Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure. 
Posted by at No comments:

Eye Care Supplements Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Eye Care Supplements Market Information: By Type (Antioxidant, Fatty Acids, Anti-Inflammatory), Application (Eye Health, Macular Degeneration, Cataract, Glaucoma, Diabetic Retinopathy), End User (Eye Hospitals, Eye Clinics) - Global Forecast till 2023
Eye care supplements market growth is expected to show an exponential rate owing to an increasing prevalence of eye diseases and chronic diseases such as diabetes, which are risk factors for eye disease. Furthermore, demand for eye care solutions is increasing across the globe. Therefore, majority of the market players have great opportunities in this market by using strategic approaches such as geographical expansion.
According to the World Health Organization (WHO) estimates, about 285 million people are visually impaired worldwide. According to the Royal National Institute of Blind People (2016), the number of people living with sight loss is expected to reach 2.7 million by 2030 due to possible cases of refractive error, cataract, glaucoma, and others. According to the National Eye Institute, the number of people in the U.S. with cataract is projected to double from 24.5 million in 2010 to 50 million by 2050. Moreover, in 2015, National Eye Institute stated that more than half of the Americans suffer from cataract-related problems in their lifespan.
Segments                                                                                                                                            
The global eye care supplements market is segmented on the basis of type, application, and end user.
On the basis of type, market is segmented into Antioxidant, Fatty acids, anti-inflammatory supplements, neuro-protective supplements and others. Antioxidant segment is further segmented into water -soluble antioxidants including lutein, zeaxanthin, astaxanthin, and fat-soluble antioxidants including astaxanthin. Fatty acids segment is further segmented into omega-6 gamma-linolenic acid. Anti-inflammatory supplements segment is further segmented into docosahexaenoic acid (DHA). Neuro-protective segment is further segmented into eicosapentaenoic acid (EPA).
On the basis of application, the market is segmented into eye health, macular degeneration, cataract, Diabetic retinopathy, glaucoma, and others.
On the basis of end user, the market is segmented into eye hospitals, eye clinics, and others.
Growing Eye Diseases and Disorders Is the Prime Determinant of the Market Growth
Eye care supplements are products containing vitamins and other nutrients that are useful for maintaining eye health and good vision. They improve eye health and can be used for the treatment of a number of related diseases such as cataracts, diabetic retinopathy, and glaucoma. Many people face the problem of poor vision. The primary method of improving the vision is use of dietary products extracted from both natural and synthetic sources such as plants. Antioxidants, omega fatty acids are the most widely used eye care supplements across the globe. 
Key Players  
Some of the key players in this market are
  • Biosyntrx Inc. (U.S.),
  • Nordic Naturals Inc. (U.S.),
  • Bristol-Myers Squibb Company (U.S.),
  • Healths Harmony USA Supplements LLC (U.S),
  • NUSAPURE (U.S.),
  • Vitabiotics Ltd. (U.K),
  • Bausch & Lomb Incorporated. (U.S.).
Market Dynamics
Growing Awareness and Geriatric Population Is Charging A High Market Demand
According to the Economic and Social Commission estimates for Asia and the Pacific, in 2016 about 12.4 % of the population within the region aged 60 or more and this geriatric population is projected to reach 1.3 billion by 2050. Increasing prevalence of eye diseases and chronic diseases such as diabetes, which are risk factors for eye disease is another driver of the market.
High Cost and Lack Of Healthcare Coverage And Infrastructure In Developing Regions Expected To Hamper Market Growth
The high cost of eye care supplements may restrain the market growth, especially in the developing countries.
Regional Analysis                    
America is the largest market for eye care supplements owing to an increasing demand for eye care supplements and rising prevalence of vision impairment and problems among people in the US. According to the Center of Disease Control and Prevention, nearly 14 million Americans aged 12 years and older have some form of visual impairment.
According to the World Health Organization, about 60 million European have diabetes and the prevalence of diabetes is relatively high among people over 25 years.
Europe is the second largest market for eye care supplements which will steady growth in the near future du rot the availability of cost effective treatments and prevention strategy.
The Middle East & Africa also show a steady rise in the market owing to rise in the demand for ophthalmic products and available treatment options.
In Asia Pacific, the market is expected grow at a fastest rate owing to an increasing prevalence of chronic disease such as diabetes, diabetic retinopathy and obesity.
Posted by at No comments:

Worldwide Oral Thrush Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Market Scenario
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand  other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of  HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.
Apart from common Oral Thrush symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.
Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high  carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.
Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.
The global oral thrush treatment market is expected to reach USD 9.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Key Players in the Global Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.
Segmentation:
The global oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.
Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.
Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
Globally, the North America market dominates the Oral Thrush market. Factors such as the well-spread awareness among people towards the oral hygiene and healthcare along with the extensive use of medications and high expenditure on the health care and augmenting uptake of new products primarily in the US drive the market growth in the region.
The Europe market accounts for the second-largest market for Oral Thrush owing to the proliferation of healthcare sector, the presence of well-established players and growing healthcare expenditures in the region. Indeed, the resurging economy is the main driving force increasing the market value in the region.
Simultaneously, the presence of the leading global players in the region is some of the key factor substantiating the growth of the regional market. Witnessing a widening uptake of oral hygiene products across the region, the North America market for Oral Thrush is likely to continue its dominance throughout the assessment period.  The North American market significantly contributing to the GDP is expected to register a significant CAGR during the forecast period.
The Europe healthcare industry is currently booming given the increasing number of medical professionals and growing awareness in the region. Moreover, the high influence of media and the rise in the awareness regarding oral hygiene especially in the countries such as Germany and France drive the European oral thrush market.
The Asia Pacific Oral Thrush market emerging as the fastest growing market accounts for a substantial market share on the global platform. Factors such as the proliferation of healthcare sector in populous countries such as India and China substantiate the market growth in the region. 
Furthermore, factors such as augmenting demand for high standards and high-quality oral care products along with the growing technological advancement are estimated to increase the market scope, boosting the demand for effective oral care treatments in the region.
Posted by at No comments:

Global Cardiovascular Needle Market Recent Trends, Growth Opportunities, Forecast By Application And Types To 2023

Market Insights:
According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population had diabetes, which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. Furthermore, increasing prevalence of population suffering from cardiovascular diseases, diabetes, and obesity driving the growth of the cardiovascular needles market globally.
The global cardiovascular needles market is growing rapidly owing to its application in various fields such as open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.
According to the World Health Organization (WHO) in 2015, around 1.6 million deaths were directly caused by diabetes and in 2014, 8.5% of adults aged 18 years and older had diabetes. Thus, rising prevalence of chronic diseases is majorly driving the global cardiovascular market.
According to the World Health Organization (WHO), in 2015, around 17.7 million people died from cardiovascular diseases, which represents 31% of all global deaths. Of these deaths, around 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
Various factors are adding fuel to the growth of the global cardiovascular needle market, such as unhealthy diet, low physical activities, etc. According to a research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market.
Moreover, advancing technology in the medical devices is adding fuel to the growth of the market. Furthermore, increasing government support in the developing countries drive the market growth.
However, increasing use of surgical staples instead of needles and suture can deter the demand for cardiovascular needles.
The global cardiovascular needle market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.
Key Players
Some of the key the players in the market are Becton, Dickinson, and Company (US), B. Braun Melsungen AG (Germany), Sheffield Ltd. (UK), CP Medical, Inc. (the US), Ethicon Inc. (US), KLS Martin Group (US), Sklar Surgical Instruments (US), Rumex International Corporation Ltd. (US), Scanlan International Inc. (US), Teleflex Incorporated (US), Medline Industries, Inc. (US), Surgins surgical Ltd. (UK), Surtex Instruments Ltd. (UK), Cardivon Surgical Inc. (China), Symmetry Surgical Inc. (US), Delacroix-Chevalier (France), Wexler Surgical (US), Quality Needles Pvt. Ltd. (India), FSSB surgical needles GmbH (Germany)
Segmentations
The global cardiovascular needle market is segmented on the basis of types, by application, by usage, and by the end user.
On the basis of the type, it is segmented into round bodied needles and cutting needles. Furthermore, round-bodied needles segmented into taper point needles and blunt point needles. Also, cutting needles segmented into conventional cutting needles and reverse cutting needles.  
On the basis of the application, it is segmented into open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.  
On the basis of the usage, it is segmented into single use and multiple uses.
On the basis of the end user, it is segmented into hospitals, clinics, ambulatory surgical centers, and others.
Regional Analysis
The Americas dominate the global cardiovascular needle market owing to the rising prevalence of diabetes, obesity, and cardiovascular diseases. Furthermore increasing government support for research & development have fuelled the growth of the market in this region. According to the American Heart Association, in 2017, cardiovascular disease listed as the underlying cause of death which is likely to account for nearly 801,000 deaths in the US by the end of this year. It further estimated that about 2,200 Americans die of cardiovascular disease each day.
Europe holds the second position in the global cardiovascular needle market owing to the presence of major players. Although companies within this region are also involved in export to the developing countries which leads the market of Europe.
The Asia Pacific is the fastest growing Cardiovascular Needle market owing to the high presence of a patient with cardiovascular disease. Furthermore, the government of this region is looking forward to better the quality of needles, which increases the demand for cardiovascular needle market in this region.
On the other hand, in the Middle East and Africa hold the least market due to low research and development activities and poor healthcare infrastructure.
Posted by at No comments:

Global Cerebral Palsy Market Expected Tremendous Growth Till 2023

Market Scenario
Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Regional Summary
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Key players
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Posted by at No comments:
Subscribe to: Posts (Atom)